نتایج جستجو برای: pteridine reductase

تعداد نتایج: 44314  

2011
Han B. Ong Natasha Sienkiewicz Susan Wyllie Alan H. Fairlamb

BRUCEI AND LEISHMANIA MAJOR Han B. Ong, Natasha Sienkiewicz, Susan Wyllie and Alan H. Fairlamb From the Division of Biological Chemistry & Drug Discovery, College of Life Sciences, University of Dundee, Wellcome Trust Biocentre, Dundee, Scotland DD1 5EH, UK Running title: Essential role of T. brucei PTR1 in recycling dihydropterins Adress correspondence to Professor Alan H. Fairlamb, Division o...

2017
Pasquale Linciano Alice Dawson Ina Pöhner David M. Costa Monica S. Sá Anabela Cordeiro-da-Silva Rosaria Luciani Sheraz Gul Gesa Witt Bernhard Ellinger Maria Kuzikov Philip Gribbon Jeanette Reinshagen Markus Wolf Birte Behrens Véronique Hannaert Paul A. M. Michels Erika Nerini Cecilia Pozzi Flavio di Pisa Giacomo Landi Nuno Santarem Stefania Ferrari Puneet Saxena Sandra Lazzari Giuseppe Cannazza Lucio H. Freitas-Junior Carolina B. Moraes Bruno S. Pascoalino Laura M. Alcântara Claudia P. Bertolacini Vanessa Fontana Ulrike Wittig Wolfgang Müller Rebecca C. Wade William N. Hunter Stefano Mangani Luca Costantino Maria P. Costi

Pteridine reductase-1 (PTR1) is a promising drug target for the treatment of trypanosomiasis. We investigated the potential of a previously identified class of thiadiazole inhibitors of Leishmania major PTR1 for activity against Trypanosoma brucei (Tb). We solved crystal structures of several TbPTR1-inhibitor complexes to guide the structure-based design of new thiadiazole derivatives. Subseque...

Journal: :Acta crystallographica. Section D, Biological crystallography 2004
Karen McLuskey Federica Gibellini Paulo Carvalho Mitchell A Avery William N Hunter

The structure of Leishmania major pteridine reductase (PTR1) in complex with NADPH and the inhibitor 2,4,6-triaminoquinazoline (TAQ) has been solved in a new crystal form by molecular replacement and refined to 2.6 A resolution. The inhibitor mimics a fragment, the pterin head group, of the archetypal antifolate drug methotrexate (MTX) and exploits similar chemical features to bind in the PTR1 ...

Journal: :Biochemical Society transactions 2003
W N Hunter M S Alphey C S Bond A W Schüttelkopf

The large quantity of genomic, biochemical and metabolic data on microbial pathogens provides information that helps us to select biological problems of interest and to identify targets, metabolic pathways or constituent enzymes, for therapeutic intervention. One area of potential use in developing novel anti-parasitic agents concerns the regulation of oxidative stress, and we have targeted the...

Journal: :Molecules 2017
Flavio Di Pisa Giacomo Landi Lucia Dello Iacono Cecilia Pozzi Chiara Borsari Stefania Ferrari Matteo Santucci Nuno Santarem Anabela Cordeiro-da-Silva Carolina B Moraes Laura M Alcantara Vanessa Fontana Lucio H Freitas-Junior Sheraz Gul Maria Kuzikov Birte Behrens Ina Pöhner Rebecca C Wade Maria Paola Costi Stefano Mangani

Flavonoids have previously been identified as antiparasitic agents and pteridine reductase 1 (PTR1) inhibitors. Herein, we focus our attention on the chroman-4-one scaffold. Three chroman-4-one analogues (1-3) of previously published chromen-4-one derivatives were synthesized and biologically evaluated against parasitic enzymes (Trypanosoma brucei PTR1-TbPTR1 and Leishmania major-LmPTR1) and pa...

2010
Lindsay B. Tulloch Viviane P. Martini Jorge Iulek Judith K. Huggan Jeong Hwan Lee Colin L. Gibson Terry K. Smith Colin J. Suckling William N. Hunter

Pteridine reductase (PTR1) is a target for drug development against Trypanosoma and Leishmania species, parasites that cause serious tropical diseases and for which therapies are inadequate. We adopted a structure-based approach to the design of novel PTR1 inhibitors based on three molecular scaffolds. A series of compounds, most newly synthesized, were identified as inhibitors with PTR1-specie...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید